• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Hypertrophic cardiomyopathy (HCM) is a relatively common often inherited global heart
disease, with complex phenotypic and genetic expression and natural history, affecting both …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline
provides recommendations and algorithms for clinicians to diagnose and manage …

Hypertrophic cardiomyopathy (HCM) is a common, serious, genetic heart disorder. Rare
pathogenic variants in sarcomere genes cause HCM, but with unexplained phenotypic …

Hypertrophic Cardiomyopathy HCM is the most common genetic disorder of the heart, with 1
case per 200 to 500 persons, and often remains clinically silent. HCM is the most common …

Arrhythmogenic cardiomyopathy (ACM) is an arrhythmogenic disorder of the myocardium
not secondary to ischemic, hypertensive, or valvular heart disease. ACM incorporates a …

Background: A better understanding of the factors that contribute to heterogeneous
outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically …

In the absence of contemporary, population-based epidemiological studies, estimates of the
incidence and prevalence of the inherited cardiomyopathies have been derived from …

Abstract Background: The HCMR (Hypertrophic Cardiomyopathy Registry) is a National
Heart, Lung, and Blood Institute–funded, prospective registry of 2,755 patients with …